Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

Patients with atopic dermatitis had an increased risk for COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic dermatitis. “The results of this study suggest that race and ethnicity do not ...

Sanofi and Regeneron’s dupilumab has been given a priority ... patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), and is the first to inhibit signalling of IL ...

Your provider may recommend oral immunosuppressants like Neoral (cyclosporine) or an injectable biologic like Dupixent (dupilumab) for severe atopic dermatitis. Immunosuppressants calm the immune ...

Further information NICE will not progress with an appraisal for this indication due to positive guidance in the adult population within TA534. NHS England and Improvement will commission treatments ...

Pregnant patients with T2IDs using dupilumab did not have an increased rate of adverse events when compared with patients not receiving dupilumab.